-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Aligos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q2 2024.
- Aligos Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$26.4M, a 38% decline year-over-year.
- Aligos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$93.5M, a 10.4% decline year-over-year.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$88.1M, a 9.69% increase from 2022.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$97.6M, a 24% increase from 2021.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$128M, a 31.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)